Abeona Therapeutics' ABO-503 Gene Therapy Chosen for FDA's Rare Disease Endpoint Advancement Pilot Program

Strategic Insights -

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, has announced that its ABO-503 gene therapy for X-linked retinoschisis (XLRS) has been selected for the U.S. Food and Drug Administration's (FDA) Rare Disease Endpoint Advancement (RDEA) Pilot Program. This program aims to support the development and timely approval of rare disease therapies by facilitating the use of novel efficacy endpoints in clinical trials. The selection of ABO-503 marks a significant milestone for Abeona, as it will provide opportunities for enhanced communication and collaboration with the FDA, ultimately accelerating the development and validation of product-specific novel efficacy endpoints for XLRS. XLRS is a rare, monogenic retinal disease that affects approximately 35,000 individuals in the United States and Europe combined, resulting in irreversible loss of photoreceptor cells and severe visual impairment.

Key Takeaways:

  • ABO-503, a gene therapy for X-linked retinoschisis (XLRS), has been selected for the FDA's Rare Disease Endpoint Advancement (RDEA) Pilot Program, which aims to support the development and timely approval of rare disease therapies.
  • The RDEA program will provide Abeona with opportunities for enhanced communication and collaboration with the FDA, including frequent advice and regular ad-hoc conversations to accelerate the development and validation of novel efficacy endpoints for XLRS.
  • XLRS is a rare, monogenic retinal disease affecting approximately 35,000 individuals in the United States and Europe combined, resulting in irreversible loss of photoreceptor cells and severe visual impairment.
  • ABO-503 has shown preclinical efficacy in a mouse model of XLRS, demonstrating structural and functional improvements following robust RS1 expression throughout the retina.
  • Abeona anticipates completing IND-enabling studies by the second half of 2026.
  • Abeona's novel gene therapy approach for XLRS involves the use of a functional human RS1 gene packaged in the novel AIM capsid AAV204.
  • ABO-503 has the potential to reverse or stabilize disease progression at early stages and prevent vision loss in individuals affected by XLRS.

Statistics:

  • The incidence of XLRS is estimated to be between 1 in 5,000 and 1 in 20,000 in males.
  • Affects approximately 35,000 individuals in the United States and Europe combined.
  • Only disease-modifying therapies are approved for XLRS.

Sources:

  • Globally sourced news article (Cleveland, OH; GLOBE NEWSWIRE).
  • Molday RS, Kellner U, Weber BH. X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms. Prog Retin Eye Res. 2012;31:195-212.
  • Sikkink SK, Biswas S, Parry NR, Stanga PE, Trump D. X-linked retinoschisis: an update. J Med Genet. 2007;44:225-232.